Technology platform

DIMA biotech has generated more than hundreds of the target specific B cell seed libraries and rabbit monoclonal antibodies (mAbs) against various druggable targets. All mAbs with IgG sequence available are FACS and ELISA validated. Biopharmaceutical customers can directly analyze the druggability of these pre-developed and validated mAbs molecules to accelerate the progress of their drug discovery. They don’t need to go through the high-risk and time-consuming lead molecules discovery stage internally or count on CRO companies for the screening of lead molecules. More+

Compared with the traditional monoclonal antibody preparation platform for hybridoma, we do not need to carry out hybridoma fusion. We can directly obtain positive B cells from peripheral blood of immunized animals after animal immunization and sequence the gene of monoclonal antibody. More than 1000 positive B cell clones can be obtained from a single immunized animal, and the overall positive clone rate is far higher than that of the traditional hybridoma platform. More+

For druggable targets, DIMA will construct ECD-Fc fusion protein and use HEK293 mammalian expression system for production. This will not only ensure the authentic posttranslational modifications from mammalian cells, but also have a high chance of obtaining proteins in good solubility and correct folding under standard buffer system. More+
Products and services
about us

DIMA Biotechnology LTD is a research and development company of recombinant monoclonal antibody focusing on immune oncology products and services. DIMA’s proprietary B cell cloning and recombinant monoclonal antibody development platform, DimAb, can efficiently generate high-quality monoclonal antibodies in high throughput. The R&D team has many years of experience in monoclonal antibody development. We provide solutions for scientific research, clinical diagnosis and therapeutic R&D. More+

news center


AddressWuhan institute of Biotechnology B7, Biolake No.666 Gaoxin Road, Wuhan, Hubei, China

Follow Us On